Previously, we identified PDGFRB fusions as a major driver of B-ALL IF, allowing the use of targeted therapy.4 To identify analogous targetable lesions in T-ALL IF, we performed WGS on 48 cases (Fig 1A); 33 cases had paired germline material available, and 37 cases underwent RNAseq (Data Supplement [Table A7]). The gene discussed is PDGFRB; the disease is acute lymphoblastic leukemia.